« Back to Farmacia Journal 5/2026

EFFICACY AND SAFETY OF TIROFIBAN IN THE TREATMENT OF ACUTE ISCHEMIC STROKE BASED ON WEB OF SCIENCE DATABASE: A META-ANALYSIS

RUI ZHANG ¹*, ZHIYUN WANG ¹

Download Full Article PDF

The study aimed to explore the clinical efficacy and safety of tirofiban in the treatment of acute ischemic stroke (AIS) through a systematic review. The Web of Science database was searched using keywords including “tirofiban”, “acute ischemic stroke”, and related medical subject terms. Eight relevant articles were identified, published between 2013 and 2020 and meta-analysis of the extracted data was subsequently conducted using RevMan 5.3 statistical software. The results showed that the odds ratio (OR) of efficacy of tirofiban in AIS was found to be 1.36, and the effect was better than that without tirofiban; the OR of good prognosis of tirofiban in AIS was 1.36, which was better than that without tirofiban in good prognosis; the OR of bleeding in AIS treated with tirofiban was 1.09, which was not significantly different from that without tirofiban; the OR of recanalization in AIS treated with tirofiban was 1.51, which was better than that without tirofiban in recanalization; the OR of mortality in AIS treated with tirofiban was 0.88, which was lower than that without tirofiban in mortality. In conclusion, Tirofiban treatment of AIS can improve the prognosis of patients, improve the response rate after treatment, improve the ability of patients to live autonomously, and can reduce the risk of reocclusion and mortality.